Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
45.48
-1.82 (-3.85%)
Oct 21, 2026, 4:08 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,922 employees as of June 30, 2026. The number of employees increased by 479 or 33.19% since the number was reported on December 31, 2025. That makes Biocytogen Pharmaceuticals (Beijing) the 10,504th largest employer in the world and 779th in Hong Kong.
Employees
1,922
Change
479
Growth
33.19%
Revenue / Employee
1.02M HKD
Profits / Employee
220.02K HKD
Market Cap
39.01B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,922 | 479 | 33.19% |
| Dec 31, 2025 | 1,443 | 326 | 29.19% |
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| Akeso | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
| Zai Lab | 1,784 |
Biocytogen Pharmaceuticals (Beijing) News
- 3 months ago - Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals - South China Morning Post
- 3 months ago - Court Clears Biocytogen's RenNano® in Landmark Patent Dispute Against Harbour - Business Upturn
- 8 months ago - Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration - Business Upturn
- 1 year ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 1 year ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 1 year ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 1 year ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 1 year ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn